🇺🇸 US Stock Screener ← Switch market ⚡ HerAI

GT Biopharma, Inc. GTBP PHARMA

Healthcare · Biotechnology · United States
https://www.gtbiopharma.com
Company Profile ↓
$5.24
+211.88% 1Y
Mkt Cap$9.45M
P/E0.04
P/B3.59
52W High$6.02
52W Low$0.25
Book Value$2.00
EPS (TTM)$130.25

Company Overview

GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) platforms. It develops GTB-3650, which is in phase 1 trials that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550, that is in phase 1 dose escalation basket trial that targets B7-H3 on the surface of advanced solid tumors;and GTB-7550, a pre-clinical stage product candidate in development for the treatment of lupus and other autoimmune disorders. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in San Francisco, California.

Why Investors Should Care

Reasonable Valuation

Trades at a P/E of 0.0, below the sector median of 24.8.

Growth & Price Performance

Stock Price Performance

1 Year:+211.88%
6 Months:+1,137.19%
3 Months:+1,132.24%
1 Month:+1,537.34%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 86% of range
$0.25 $6.02
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • Golden Cross1d ago
  • RSI (14)85.98 · Overbought
Price Performance
1M+1,537.34%
3M+1,132.24%
6M+1,137.19%
1Y+211.88%
Valuation vs Sector

P/E of 0.04 is below the sector median of 24.83 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • RSI at 86 suggests overbought conditions.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
0.04
Industry PE
24.83
Forward P/E
-0.49
PEG Ratio
1.05
Book Value
$2.00
Price to Book
3.59
P/S
-
EV/EBITDA
-
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
-
Profit 5Y
-
Revenue (YoY)
-
Earnings (YoY)
-

Profitability & Returns

ROCE
-
ROE
-113.52%
ROA
-
Profit Margin
0.00%
Op Margin
0.00%
Gross Margin
0.00%
EPS (Latest Qtr)
$-0.11
EPS (TTM)
$130.25

Balance Sheet & Liquidity

Debt/Equity
-
Quick Ratio
2.23
Current Ratio
2.61
Debt
$0
Total Assets
$10.00M
Current Assets
$10.00M
Working Capital
$7.58M

Ownership

Promoter Holding
5.71%
Chg in Prom Hold
-
FII / Inst Holding
4.70%
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
$9.45M
Total Revenue (TTM)
$0
EBITDA
-
Free Cash Flow
$-8.87M
Operating Cash Flow
$-14.43M
Shares Outstanding
1.80M
Gross Margin
0.00%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 GTBP GT Biopharma, Inc. PHARMA 5.24 0.04 $9.45M 0.00% - -113.52% - -
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,123.91 37.80 $1.00T 0.60% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 269.12 31.22 $648.55B 1.98% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 248.78 70.48 $439.62B 2.78% 10.47% -129.24% 1.75% -29.06%
5 MRK Merck & Co., Inc. SPXR3KPHARMA 148.46 118.77 $366.28B 2.31% - 6.96% 5.64% 10.01%
6 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 400.84 25.74 $359.79B 2.47% 9.74% 14.15% 10.40% 5.43%
7 NVS Novartis AG PHARMA 137.70 20.80 $261.73B 3.36% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 160.04 23.99 $248.20B 2.00% 15.97% 21.96% 9.82% 45.96%
9 TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA 603.02 32.49 $222.97B 0.29% 8.14% 13.51% 8.81% 12.95%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Mar 2013Jun 2013Sep 2013Mar 2014Jun 2014Sep 2014Mar 2015Jun 2015Sep 2015Mar 2016Jun 2016Sep 2016Mar 2017Jun 2017Sep 2017Mar 2018Jun 2018Sep 2018Mar 2019Jun 2019Sep 2019Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Mar 2026
Revenue -------------0-00-0--000000-------------
Gross Profit 19.00K44.00K60.00K08.00K-2.00K7.00K20.00K000000000-0--0------------------
Operating Income -347.00K-74.00K-140.00K-101.00K-104.00K-549.00K-1.81M-1.43M-2.78M-3.90M-2.12M-2.53M-1.54M-1.28M-126.86M-7.16M-5.16M-234.66M-4.06M-2.28M-8.86M1.07M-1.56M-1.95M-29.00M-4.38M-5.95M-5.44M-3.01M-7.02M-3.67M-3.62M-3.12M-3.09M-3.91M-3.60M-1.93M-1.51M-3.38M-2.85M
Net Income 468.00K-306.00K-319.00K-371.00K-262.00K-4.22M-20.52M26.86M-1.69M25.95M1.54M-3.63M-5.06M-2.46M-130.62M-10.09M-9.08M-235.78M-4.51M-2.79M-29.88M-1.71M-17.42M-2.88M-29.68M-4.86M-5.45M-5.44M-2.98M-6.88M-227.00K-1.99M-2.42M-2.27M-3.71M-3.41M-776.00K-30.17M8.30M-2.83M
Diluted EPS 0.000.00-0.000.00-0.01-8.614,907,238.000.711.4918.22-39.65-26.36479,053.00-8.15-0.2050,117,977.00-4.70-0.09---0.02-------0.10-0.22-0.21-1.49-1.77-1.64-2.17-1.53-0.33-10.921.04-0.11
R&D Expense 000000250.00K0225.00K225.00K250.00K250.00K144.00K241.00K526.00K3.47M3.25M1.11M834.00K154.00K671.00K324.00K12.00K84.00K1.64M639.00K1.01M2.09M1.14M2.74M1.65M2.10M1.36M777.00K1.78M1.31M1.10M363.00K634.00K413.00K

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 11.00K26.00K342.00K368.00K61.00K27.00K00-00-----
Gross Profit -54.00K-22.00K248.00K142.00K4.00K27.00K00--------
Operating Income -2.50M-3.93M-3.51M-793.00K-2.40M-8.93M-9.37M-135.57M-250.07M16.06M-6.76M-57.52M-21.26M-13.58M-14.36M-12.42M
Net Income -3.00M-3.70M-5.17M-501.00K-23.49M-32.73M9.77M-144.17M-259.19M-38.65M-28.30M-58.01M-20.88M-7.60M-13.16M-28.35M
Diluted EPS ------119.91-8.60-5.16----19.66-5.64-6.94-6.68
R&D Expense 179.00K17.00K0001.00M975.00K1.07M9.07M1.67M485.00K9.59M8.81M6.47M5.80M3.47M

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Sep 2012Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Jun 2020Sep 2020Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Jun 2025Sep 2025Dec 2025
Total Assets -185.00K129.00K-226.00K147.00K888.00K54.00K25.00K254.37M25.40M396.00K--5.66M32.17M16.74M14.11M4.23M7.12M4.32M8.11M
Total Equity --5.47M-5.10M--6.34M-6.33M-29.57M-61.83M-18.92M251.69M11.37M-19.31M-27.50M-29.78M-29.43M21.91M11.73M7.48M-1.67M-25.88M3.00M5.79M
Cash & Equivalents 1.29M54.00K92.00K61.00K123.00K43.00K855.00K47.00K19.00K576.00K60.00K28.00K--5.30M8.97M5.67M1.08M3.95M--6.81M
Total Liabilities -5.65M5.23M-6.56M6.48M30.46M61.89M18.95M2.68M14.03M19.71M---10.26M5.00M6.63M-31.04M1.32M-
Current Liabilities -5.65M5.23M-6.56M6.38M29.83M61.17M18.95M2.68M14.03M19.71M--35.09M10.26M4.94M6.63M5.90M--2.32M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -1.53M-963.00K-987.00K-442.00K-1.75M-4.66M-1.93M-5.43M-10.68M-3.66M-7.26M-15.61M-15.22M-8.85M-12.90M-12.91M
Investing Cash Flow -0-2.00K0-6.00K-1.00K0-4.00K-36.00K200.00K0-23.04M12.14M-2.01M12.89M-
Financing Cash Flow 296.00K1.00M930.00K425.00K2.58M3.85M1.90M5.99M10.20M3.43M12.53M42.32M-224.00K6.27M2.98M15.78M
Capital Expenditure --0-2.00K-0-6.00K-1.00K-0-4.00K-36.00K-0------
Free Cash Flow --963.00K-989.00K-442.00K-1.75M-4.66M-1.93M-5.43M-10.71M-3.66M------
Dividends Paid ---------------229.00K

Ratios (Annual)

Figures in %.

Metric Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % -490.9%-84.6%72.5%38.6%6.6%100.0%----------
Operating Margin % -22,700.0%-15,107.7%-1,027.5%-215.5%-3,927.9%-33,063.0%----------
Net Margin % -27,227.3%-14,230.8%-1,512.0%-136.1%-38,506.6%-121,207.4%----------
ROE % 54.8%72.5%81.6%7.9%79.4%52.9%-51.6%-57.3%-2,279.6%200.1%96.1%-264.8%-178.0%-101.6%788.1%-490.0%
ROCE % 45.7%77.0%55.5%12.7%8.3%14.6%49.5%-53.9%-2,199.4%-83.1%23.0%-262.5%-180.2%-181.6%860.1%-214.7%

Shareholding Pattern

Insiders
5.71%
Institutions
4.70%
Public Float
-

Top Institutional Holders

#Holder% HeldSharesValue
1 Vanguard Capital Management LLC 0.83% 15.06K $107.80K
2 Geode Capital Management, LLC 0.59% 10.67K $76.40K
3 Vanguard Fiduciary Trust Co 0.50% 9.04K $64.71K
4 HRT Financial LP 0.24% 4.29K $30.69K
5 Everhart Financial Group, Inc. 0.22% 4.00K $28.64K
6 Arax Advisory Partners 0.21% 3.75K $26.81K
7 Opal Wealth Advisors, LLC 0.18% 3.27K $23.43K
8 Northern Trust Corporation 0.17% 3.02K $21.61K
9 Alongside, LLC 0.14% 2.56K $18.33K
10 49 Wealth Management, LLC 0.14% 2.56K $18.33K

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for GTBP

Google News Fri, 04 Sep 2026

symbol__ Stock Quote Price and Forecast - CNN

<a href="https://news.google.com/rss/articles/CBMiUEFVX3lxTFBmaUVDQzdIeFl0YVppb3ltVDl4Y0RPSGowRUlsUTNxTktXRTFpcERuRmdEeDl0U1BydENlSFVXam96SC1qcVV5UzhYWll6enMw?oc=5" target="_blank">symbol__ Stock Quote Price and Forecast</a>&nbsp;&nbsp;<fon…

Google News hu, 25 Jun 2026

GTBP Forecast — Price Target — Prediction for 2027 - tradingview.com

<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTFBmaldMaWJOa0VYdnFrMGc4OU90R1g1V0xNTkNUTGFvVmdvLW9FOVRPcENqM0hyeVJFRmxpRy1TRUtUcllZTV9nQlkyTEN4LUV5djN4QWV0UzlqZ3F6clJEdV9pVDlyVTFmLU9Uam10bzlSM1ZPNno5UFlB?oc=5" target="_blank">GTB…

Google News Mon, 16 Mar 2026

GT Biopharma (GTBP) Upgraded to Buy: Here's What You Should Know - finance.yahoo.com

<a href="https://news.google.com/rss/articles/CBMiggFBVV95cUxPYV9BQy1DMUNQWVRfWE1yTG9fY0p2UVpBc3pFWk1tRUxrUlNuaDhSVVZCTXBRN0VRYVh5ZGozRGlLT1RJa0p2dlJub0ZJWi1YSTd2NzVFdzdYV2NzV0JwQ3B2c2pBYTNyOHNnX1BZVFl0cE9WdnoxSENPSGswRUFKMjVB?oc=5" target=…

Google News Fri, 17 Apr 2026

GTBP | GT Biopharma Inc. Common Insider Trading - Quiver Quantitative

<a href="https://news.google.com/rss/articles/CBMiXEFVX3lxTFBlZE9vQ1ItSktqV2pOdHVkcEVzX2diUnFQMGxZc0NwZEpTa0FoeEJKSHE0UUFjTHZlQXo1RVU5MVNwcE4zcVpLenRvTDBSRFRvRE1JWUpVckNxcnM5?oc=5" target="_blank">GTBP | GT Biopharma Inc. Common Insider Tra…

Google News Fri, 14 Aug 2026

GT Biopharma (NASDAQ: GTBP) wins approval for reverse split and share plan changes - Stock Titan

<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxPUGlxQXlFWE9oMlRBX1lDWlNFbWNIRHFPTlFabUZpNlBRYmJzRTF1VURUa0hhV1hVRFc2S0hNR0ZNWHBVbG85NmNPOFJDcDFoM0I5VHE5STZITjI0UU5HQVBWUTg3QTJEQ205bjhscmxadFZsYVRxTXhLV2RsTGdwdzIzdldXcmsyNTFMM0…

Google News ue, 26 May 2026

GTBP - Finviz

<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE5Rb1E1QWh0R0pkUEc3WkxYSTFBWmp3ODJueFRBRk12dHdSOUdmVDJ5c0V3TlcyLUd2ZUVqRVRJODlFUGZhWEE?oc=5" target="_blank">GTBP</a>&nbsp;&nbsp;<font color="#6f6f6f">Finviz</font>…

GTBP — Frequently Asked Questions

What is the current share price of GT Biopharma, Inc. (GTBP)?

As of 2026-09-19 21:16 PDT, GT Biopharma, Inc. (GTBP) trades at $5.24 on NasdaqCM. Its 52-week range is $0.25 to $6.02.

What is the market capitalisation of GTBP?

GT Biopharma, Inc. (GTBP) has a market capitalisation of $9.45M on NasdaqCM.

What is the P/E ratio of GTBP?

GTBP trades at a trailing price-to-earnings (P/E) ratio of 0.04. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 3.59.

What is the return on equity (ROE) of GTBP?

GTBP has a return on equity (ROE) of -113.52%.

Is GTBP a good stock to buy?

This page provides a data-driven analysis of GT Biopharma, Inc. (GTBP), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space